Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA

BACKGROUND: In the USA, drug costs associated with the inhaled corticosteroid (ICS) and long acting β agonist (LABA) combination products have been increasing since 2001. In January 2019, the first generic ICS/LABA drug product was approved by the U.S. Food and Drug Administration. METHODS: We inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhong, Ahluwalia, Sharon K., Newman, Bryan, Dhapare, Sneha, Zhao, Liang, Luke, Markham C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812951/
https://www.ncbi.nlm.nih.gov/pubmed/35118630
http://dx.doi.org/10.1007/s43441-021-00372-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812951/
https://www.ncbi.nlm.nih.gov/pubmed/35118630
http://dx.doi.org/10.1007/s43441-021-00372-y

Ejemplares similares